Beaumont RCSI Cancer Centre

Clinical Research

Clinical research is undertaken across the breath of cancer diseases.  Phase I, IIa, IIb and III trials are led by consultant medical oncologists, radiation oncologists, surgeons and haematologists.  Patients treated on clinical trials receive experimental therapy in the Cancer Centre either with or in lieu of other standard systemic anticancer therapy. Recent advances in cancer treatment are the direct result of high quality, prospective research and so clinical trials are consistently seen as a core component of the optimal management of patients with cancer. The importance of this is recognised in the National Cancer Strategy (2017-2026).

  • Cancer Clinical Trials and Research Unit

    The Cancer Clinical Trials and Research Unit (CCTU), Beaumont Hospital conducts clinical, translational and outcomes research in patients with cancer across the Dublin North – North East region. A key aim of the work is to learn more about the pathophysiology of malignancy and to deliver new therapies to improve quality-of-life and cancer survival, by conducting high quality research in compliance with EU, national and international regulations. Clinical trials are routinely sponsored by pharmaceutical companies or Cancer Trials Ireland. In addition to providing funding to conduct the trials, the Sponsor plays a key role in research governance to ensure that all trials are carried out in accordance with National and International standards and applicable laws, including as defined under “Good Clinical Practice” (GCP), the international ethical, scientific and practical standard to which all clinical research is conducted.

    Research is led by consultant medical oncologists and haematologists and patients treated on clinical trials receive experimental therapy in Beaumont Hospital either with or in lieu of other standard systemic anticancer therapy (SACT). Recent advances in cancer treatment are the direct result of high quality, prospective research and so clinical trials are consistently seen as a core component of the optimal management of patients with cancer. The importance of this is recognised in the National Cancer Strategy (2017-2026).

  • Open Clinical Trials

    Breast Cancer

    SASCIA

    Phase III post neoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2 negative breast cancer patients with high relapse risk after standard neoadjuvant treatment

    Cancer Centre Lead: Prof Patrick Morris

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    ZEST

    Randomized Phase 3 Double-Blinded Study Comparing The Efficacy And Safety Of Niraparib To Placebo In Participants With Either Her2-Negative Brca-Mutated Or Triple-Negative Breast Cancer With Molecular Disease Based On Presence Of Circulating Tumor DNA After Definitive Therapy (Zest)

    Cancer Centre Lead: Professor Patrick Morris

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    LidERA

    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician’s Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer

    Cancer Centre Lead: Professor Patrick Morris

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    ALEXANDRA

    A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (ANTI-PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

    Cancer Centre Lead: Professor Patrick Morris

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    CHECKMATE 7FL

    A Randomised, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

    Cancer Centre Lead: Professor Patrick Morris

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    EPIK-B5

    A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HRpositive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor

    Cancer Centre Lead: Prof Patrick Morris

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie


    Colorectal Cancer

    Krystal 10: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

    Cancer Centre Lead: Prof Liam Grogan

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie


    Upper Gastro Intestinal Cancer

    Leap 015

    A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)

    Cancer Centre Lead: Dr Adrian Murphy

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie


    Haematological Malignancies

    CPD DARA

    Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma. (The CPD-DARA Study)

    Cancer Centre Lead: Dr John Quinn

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    MOR208

    A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus RCHOP in previously untreated, high-intermediate and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)

    Cancer Centre Lead: Prof Patrick Thornton

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    Loxo 305

    A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

    Cancer Centre Lead: Dr Philip Murphy

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    Ithaca

    A Phase 3 randomized, open-label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma

    Cancer Centre Lead: Dr John Quinn

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    HOVON 150

    A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

    Cancer Centre Lead: Dr Philip Murphy

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    HOVON 156

    A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.

    Cancer Centre Lead: Dr John Quinn

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    CLL-17

    A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)

    Cancer Centre Lead: Prof Patrick Thornton

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    Medici

     MEDICI – t(11;14) and BCL2 expression in patients with multiple myeloma: Prevalence, stability across lines of therapy, and concordance across sample types.

    Cancer Centre Lead: Prof Siobhan Glavey

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    DREAMM14

    A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma

    Cancer Centre Lead: Dr John Quinn

    Contact: Mr Keith Egan (01) 8092010 keithegan2@beaumont.ie


    Lung Cancer

    KRYSTAL 12

     A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Cancer Centre Lead: Dr Jarushka Naidoo

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    MK7684A-008

    A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer

    Cancer Centre Lead: Dr Jarushka Naidoo

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie


    Urological Cancers

    KEYNOTE-641

    A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

    Cancer Centre Lead: Prof Liam Grogan

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie

    MK6482-022:

    A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK- 3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy

    Cancer Centre Lead: Dr Adrian Murphy

    Contact: Mr Keith Egan (01)8092010  keithegan2@beaumont.ie


     

  • Clinical Trial Results


    Presentation and Publication of Recent Trial Activity

    The ASCO Post: December 2020:
    RxPONDER Study Shows Postmenopausal Patients With Node Positive Breast Cancer May Be Able to Avoid Chemotherapy

    JCO Jan 2021:
    Pembrolizumab plus Ipilumumab or Placebo for Metastatic Non-Small Cell Lung Cancer with PD-L1 Tumour Proportion Score > 50%: Randomised, Double Blind Phase III KEYNOTE 598 Study

    The Lancet Oncology Feb 2021:
    Palboclib with adjuvant endocrine therapy in early breast cancer (PALLAS): Interim analysis of a multicentre, open label, randomised phase 3 study

    Cancers Mar 2021:
    Phase 1b Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “Panther”

    NEJM Apr 2021:
    Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

    JCO May 2021:

    Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer – The Penelope B Trial